文献速递眼底病与葡萄膜炎

玻璃体切除术中内界膜剥除治疗糖尿病性玻璃体出血的随机临床试验

INTERNAL LIMITING MEMBRANE PEELING DURING VITRECTOMY FOR DIABETIC VITREOUS HEMORRHAGE: A Randomized Clinical Trial.
PubMed 文献 · Retina · 2021-01-01

结果显示A组6个月最佳矫正视力优于B组,术后糖尿病黄斑水肿治疗发生率及6个月视网膜前膜发生率均更低。

要点

  • 内界膜剥除组6个月最佳矫正视力优于未剥除组(P < 0.01)。
  • 内界膜剥除组术后糖尿病黄斑水肿治疗发生率更低(P = 0.02)。
  • 内界膜剥除组6个月视网膜前膜发生率更低(P < 0.001)。

核心结论

  • 在因玻璃体出血行平坦部玻璃体切除术的增殖性糖尿病视网膜病变受试者中,行内界膜剥除者6个月视力更好、术后糖尿病黄斑水肿治疗更少、视网膜前膜发生率更低。

主要发现

  • A组6个月最佳矫正视力优于B组(P < 0.01)。
  • A组术后试验期间糖尿病黄斑水肿治疗发生率低于B组(P = 0.02)。
  • A组6个月视网膜前膜发生率低于B组(P < 0.001)。
  • A组光学相干断层扫描中心黄斑厚度有低于B组的趋势(P = 0.09)。
  • 两组基线资料及术中、术后并发症无显著差异。

关键数值与推荐

  • 主要结局为6个月最佳矫正视力。
  • 次要结局包括6个月光学相干断层扫描中心黄斑厚度、术后试验期间糖尿病黄斑水肿治疗发生率及6个月视网膜前膜发生率。

临床怎么用

  • 对因玻璃体出血行平坦部玻璃体切除术的增殖性糖尿病视网膜病变受试者,可考虑行内界膜剥除以改善6个月视力并减少术后糖尿病黄斑水肿治疗及视网膜前膜。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the benefits of internal limiting membrane peeling in proliferative diabetic retinopathy subjects undergoing pars plana vitrectomy for the treatment of vitreous hemorrhage. METHODS: Two hundred and fifty-eight proliferative diabetic retinopathy subjects undergoing pars plana vitrectomy for vitreous hemorrhage were enrolled into the trial. Patients were randomized into one of two cohorts: Group A patients underwent internal limiting membrane peeling, whereas Group B patients did not undergo internal limiting membrane peeling. The main outcome was best-corrected visual acuity at 6 months. Secondary outcomes were optical coherence tomography central macular thickness at 6 months, incidence of diabetic macular edema treatment during the postoperative trial period, and incidence of epiretinal membrane at 6 months. RESULTS: Two hundred and seven patients were randomized and completed 6 months follow-up. Group A had better best-corrected visual acuity at 6 months than Group B (P < 0.01). Group A had a lower incidence of diabetic macular edema treatment during the postoperative trial period and a lower incidence of epiretinal membrane at 6 months than Group B (P = 0.02 and P < 0.001, respectively). There was a trend toward lower central macular thickness on optical coherence tomography in Group A than Group B (P = 0.09). There were no significant differences in baseline details or complications intraoperatively or postoperatively between cohorts. CONCLUSION: This trial demonstrated better vision, fewer postoperative diabetic macular edema treatments, and a lower incidence of epiretinal membrane at 6 months when internal limiting membrane peeling was performed. Internal limiting membrane peeling may be considered a vital maneuver to perform in proliferative diabetic retinopathy subjects undergoing pars plana vitrectomy for vitreous hemorrhage.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Rush RB, Del Valle Penella A, Reinauer RM, et al. INTERNAL LIMITING MEMBRANE PEELING DURING VITRECTOMY FOR DIABETIC VITREOUS HEMORRHAGE: A Randomized Clinical Trial. Retina. 2021. PMID: 32910084. doi:10.1097/IAE.0000000000002976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。